Cue Biopharma is trading at $31.50 (14% down) after announcing a $50 million private placement of common stock and pre-funded warrants priced at approximately $33.21 per share.
- The financing represents roughly one-third of the company's market capitalization and is led by Cormorant Asset Management with participation from Columbia Threadneedle.
- The deal is expected to close on or about July 13, 2026, subject to customary closing conditions.
- Net proceeds are earmarked to fund ongoing clinical development and for general corporate purposes.